Omega-3 Prescriptions vs Supplements in Practice

Hypertriglyceridemia

Unmet Need for Adjunctive Dyslipidemia Therapy

Residual Risk of CV Events on Statin Therapy

Potential CVD Benefits

Areas of Interest for OM3FA

Suboptimal Omega-3 PUFA Consumption Among US Adults

Meta-Analysis of RCTs and PCSs Omega-3 PUFA and CHD Risk

Real-World Data Presented at ADA 2018

Omega-3 PUFA Supplementation and Prevention of Clinical CVD Science Advisory From the AHA

Dietary Supplements vs OTC Drugs vs Prescription Drugs

EPA + DHA Content in Dietary Supplements

EPA and DHA Intake Continuum of Cardioprotection

Potential Benefits of EPA and DHA

Metabolism of EPA and DHA Key Findings

The GISSI-Prevenzione Trial Post-MI

GISSI-Prevenzione Trial Results

JELIS EPA for Primary Prevention

REDUCE-IT Study Design

CV Outcomes Trials in Patients With Hypertriglyceridemia

Ongoing Clinical Trials With OM3FA

More Conflicting Results… Meta-Analysis of 10 Trials

Considerations for Evaluating Clinical Data

Reduction in CHD in Patients With High TG and Low HDL Demonstrated With Fibrates

Risk Difference vs Placebo of HTG Subgroups Primary and Secondary CVD Prevention Trials

Synergistic Effects With Statins

Allergies and Safety With Supplements

Multidisciplinary Team Strategies

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)